Our Passion for IPOs
News & Views
Largest Global IPOs
Largest US IPOs
Largest US IPOs YTD
Largest US Internet IPOs
Top First Day Returns
US IPO Stats
IPO Average Age
IPO Industry Breakdown
Offer Price Discounts
Global IPO Stats
IPOs by Region
IPO Industry Breakdown
Register for Updates
Press Contact Form
Free iPhone App
Free Android App
IPO News Feed
IPO News Archive
Interested in IPO Investing?
Weekly Recap: Xoom zips, filing activity picks up for US IPO market
Analyst IPO Blog
Money transfer service Xoom (
) surged 59% on Friday, ending 2013's first month and a half of US IPOs on a high note. Xoom's first-day pop is another positive data point, together with large money flows into equities, very low volatility and overall strong IPO returns, suggesting that the
could build quickly as more companies file audited 2012 financials.
New IPO filing activity also picked up last week, as six companies, looking to raise over $1 billion in the aggregate, were added to the
US IPO pipeline
. The IPO market remained challenging, however, for smaller, niche deals. On Thursday, Orchid Island Capital (
) became the eighth consecutive mortgage REIT to fall on its first day, and two micro-cap diagnostics companies, AutoGenomics (
) and Cancer Genetics (
), pulled their deals.
Xoom has best first-day gain since October 2012
Xoom raised $101 million on Thursday after pricing above the range. Its 59% first-day gain was the largest since on-demand software company Workday (
) popped 74% in October 2012, and the second largest since data software provider Splunk (
) more than doubled in price (gaining 108%) in April 2012. Xoom provides online and mobile money transfer services to 776,000 customers, mostly immigrants in the US. Revenue increased 60% to $80 million in 2012, although the company remained unprofitable as it invested in growth. Sequoia is the largest shareholder, with an 18% post-IPO stake; other backers include New Enterprise Associates, T. Rowe Price and DAG Ventures. Barclays and Needham were the joint bookrunners on the deal.
Two small IPOs trade relatively flat
ConnectOne Bancorp (
), a community bank serving Bergen County, NJ, and Orchid Island Capital, a mortgage REIT investing in Agency RMBS, completed small deals of $45 million and $34 million, respectively. ConnectOne specializes in an underserved market for loans of $1 million to $5 million to small- to mid-sized businesses, and it has grown assets at a rate of 22%. However, its geographic concentration, lack of a dividend and small size made it palatable to only a small group of investors. While it priced slightly above the midpoint of its proposed range, it gained a modest 4% in its first week of trading.
Orchid Island Capital currently has a $115 million portfolio, which is managed by Bimini Capital. Although Bimini once managed a $3.5 billion Agency RMBS portfolio, its array of housing-crash related issues, including two ongoing lawsuits, likely limited investors' interest in the deal, which finished the week down 3%.
Genetic testing companies postpone deals
AutoGenomics, a delayed deal from the previous week, and Cancer Genetics were the final companies on the IPO calendar entering last week, and both postponed their deals. Both companies were early stage, had substantial accumulated deficits and faced much larger competitors in the crowded testing market. They were also micro cap companies that had each initiated at least one prior IPO attempt. According to an underwriter, AutoGenomics has withdrawn its offering. Cancer Genetics has not officially withdrawn, but it will need to obtain external financing by the end of the month in order to continue operations.
With Presidents' Day resulting in a shortened week for the US financial markets and in light of the fact that all new issues with a December fiscal year end will now be required to file audited full year financials before pricing, the US IPO market is set to take a pause this week. However, new and updated filing activity suggests that the US IPO calendar could fill up quickly heading into March.
First software IPOs among six deals added to the US IPO pipeline
Last week was the most active thus far this year for initial IPO filings. The six new deals, including the first new software deals of the year, were just one shy of the seven deals added to the pipeline in all of January. Four of the six new deals added to the pipeline had previously submitted confidential filings, suggesting their deals could launch within the next three weeks. Two of the deals were previously part of our Private Company Backlog.
Marin Software (
; $75 million deal size) offers a subscription-based digital ad platform that integrates search, display and social marketing. Revenue increased 72% to $43 million for the nine months ended September 30, 2012. Venture backers include Benchmark Capital Partners, DAG Ventures, Temasek Capital, Focus Ventures and Crosslink Ventures. Goldman Sachs, Deutsche Bank, UBS and Stifel Nicolaus Weisel were listed as joint bookrunning managers for this IPO.
Model N (
; $75 million) provides software-driven revenue management solutions to life science and technology customers, including Bristol Meyers Squibb, Johnson & Johnson, Merck, Dell and Nokia. Backers include Meritech Capital Partners and Accel Partners. J.P. Morgan and Deutsche Bank are serving as joint bookrunners.
Hannon Armstrong Sustainable Infrastructure Capital (
; $100 million) is a structured REIT that provides financing for clean energy capital projects. BofA Merrill Lynch, UBS and Wells Fargo are underwriting the IPO.
On Friday, TPG and Bain-backed Quintiles Transnational (
) filed for a $600 million IPO. The largest provider of clinical trial services to pharmaceutical companies, Quintiles was the largest of three healthcare companies to enter the pipeline. TPG and Bain acquired their stakes (currently 23% each) for $3.5 billion from One Equity Partners in 2008. The company booked $4.9 billion in sales in 2012. Morgan Stanley, Barclays and J.P. Morgan are the joint bookrunners on the IPO.
Tetraphase Pharmaceuticals (
; $86 million) is a biotech creating antibiotics for life-threatening, multi-drug resistant infections and is backed by Flagship Ventures, CMEA Ventures, Skyline Venture Partners, FMR (Fidelity) and Mediphase Venture Partners. Barclays and BMO Capital Markets are serving as joint bookrunners on the deal.
The final initial filing of the week came from Sophiris Bio (
; $75 million), a pre-revenue company developing treatments for urological diseases. It is backed by Warburg Pincus (52% pre-IPO stake) and BC Advantage Funds (12%). Citi and Leerink Swann are acting as joint bookrunning managers.
Seven other companies updated filings last week. Taylor Morrison Home Corporation (
), one of America's top ten homebuilders, doubled its proposed deal size to $500 million. Blackstone-backed SeaWord Entertainment (
) chose the NYSE for its listing. Silver Spring Networks (
), which delivers hardware, software and services to improve power grid efficiency, and Artisan Partners Asset Management (
), an independent investment manager, both reported full year 2012 financials.
US IPO pipeline expands for the first time in weeks
The full IPO pipeline contains 110 companies looking to raise $31.2 billion. However, most of the flings are stale: 66 of the companies (60%) have either not released filings in the past six months or have postponed. A more promising group of companies that have released updates in the past month (excluding postponed deals) includes 23 deals seeking $6.7 billion of proceeds.
US IPO market performance update
Xoom's hot start kept recent
metrics looking strong. The average return for IPOs from the past 90 days is 25%, and the average aftermarket return is 10%. Xoom was the 20th IPO of 2013 and pushed total proceeds for the year to $5.5 billion. The average total return for the year is 18%, and the average aftermarket return is 5%.
Keywords / Tickers:
Recently Priced IPOs
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included:
IPO investment firm Renaissance Capital (www.renaissancecapital.com)
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Net Asset Value (NAV)
of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding.
is current value at which an asset or service can be bought or sold.
is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
The S&P 500® Index (SPX)
is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE. The S&P 500 index components are determined by S&P Dow Jones Indices.
Investments in the
Renaissance IPO ETF, symbol "IPO"
(the “ETF”) and the
Global IPO Fund, symbol "IPOSX"
(the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETF and the Mutual Fund (the “Funds”) invest in companies that have recently completed their initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. The Funds may also be subject to information technology risk and small and mid-capitalization company risk due to a greater number of IPOs in these sectors. The Funds may hold securities in the form of Depository Receipts, REITs, Master Limited Partnerships (MLPs) which have greater risks than common shares. The strategy has high portfolio turnover and securities lending risks. ETF returns may not match the return of the respective index. The ETF is classified as a non-diversified investment company and is subject to concentration risk.
Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with information about the Funds, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETF, 1-866-486-6645.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the
Renaissance IPO ETF (symbol: IPO)
Global IPO Fund (symbol: IPOSX)
, may have investments in securities of companies mentioned.
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2014 Renaissance Capital LLC. All rights reserved.